Video

What the re:Vive 2.0 platform may mean for the future of vision diagnostics

Author(s):

Sheryl Stevenson

Mary Durbin, PhD, Chief Scientific Officer at Heru, discusses the benefits and capabilities of the various testing modalities available in 1 wearable platform.

Mary Durbin, PhD, Chief Scientific Officer at Heru, discusses the benefits and capabilities of the various testing modalities available in 1 wearable platform with Sheryl Stevenson, Ophthalmology Times®’ Group Editorial Director.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) EyeCon 2025: Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning
Related Content
European Union flags outside a parliament building. Concept image for European Commission approval and European Medicines Agency regulatory decision on aflibercept biosimilar Mynzepli. Image credit: ©artjazz – stock.adobe.com
August 21st 2025

European Commission approves aflibercept biosimilar Mynzepli

3 Things You Should Know About the GA Pipeline
August 21st 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Image credit: SeeWhatMatters)
August 21st 2025

Q&A: AEVR's executive director on #SeeWhatMatters and safeguarding the National Eye Institute

Patient-Centered Treatment Strategies in the Management of nAMD and DME
August 21st 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Opthea parts with CEO, lays off over 80% of company
August 21st 2025

Opthea parts with CEO, lays off over 80% of company

FDA clears IND for Opus Genetics’ OPGx-BEST1 gene therapy for inherited retinal disease
August 21st 2025

FDA clears IND for Opus Genetics’ OPGx-BEST1 gene therapy for inherited retinal disease

© 2025 MJH Life Sciences

All rights reserved.